|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
INSM1 was negative in all but 1 of 91 analyzed non-neuroendocrine tumors (adenocarcinomas, squamous cell carcinomas; specificity: 99%).
|
30358615 |
2020 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
INSM1 was positive in 90 (99%) of the NET/TNEFs and negative in 32 (97%) non-NETs.
|
30502379 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have shown that INSM1 is a sensitive marker for neuroendocrine tumours.
|
31077609 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulinoma-associated 1 (INSM1) has recently been reported as a highly sensitive and specific marker that displays positivity in ~90%-100% of poorly differentiated pulmonary neuroendocrine tumors.
|
30385371 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors.
|
30796198 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
IMPLICATIONS: Neuroendocrine transcription factor (INSM1) may serve as a neuroendocrine biomarker for the development of novel cancer therapeutics against neuroendocrine tumors.
|
31113827 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients.
|
30290028 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, increasing reports indicated that INSM1 (homologue to nerfin-1 in mammals) is a useful marker for prognosis of neuroendocrine tumors.
|
29154825 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed INSM1 immunohistochemistry on a large series of thoracic neuroendocrine and non-neuroendocrine tumors and compared its performance to synaptophysin, chromogranin, and CD56.
|
28719469 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Insulinoma associated-1 (INSM1) gene is expressed exclusively in early embryonic neuroendocrine tissues, but has been found highly re-activated in most of the neuroendocrine tumors including small cell lung carcinoma.
|
27072116 |
2016 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Insulinoma associated-1 (IA-1/INSM1) gene is exclusively expressed during early embryonic development, but has been found to be re-expressed at high levels in neuroendocrine tumors including neuroblastoma.
|
26456864 |
2015 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The alterations increase the therapeutic potential of adenoviral INSM1 promoter-driven suicide gene therapy for the treatment of a variety of neuroendocrine tumors.
|
23079673 |
2012 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
INSM1 expression is normally absent in adult tissues, but is reactivated in neuroendocrine tumor cells.
|
19604042 |
2009 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The INSM1 promoter is therefore a potential novel tool for transcriptionally targeted gene therapy for neuroendocrine tumors.
|
16052225 |
2006 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The presence of several different upstream regulatory elements may account for IA-1 gene expression in different neuroendocrine tumors.
|
8188699 |
1994 |